The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome

Basit Öğe Kaydı
dc.contributor.authorCakar, Burcu
dc.contributor.authorSurmeli, Zeki
dc.contributor.authorOner, Pinar Gursoy
dc.contributor.authorYelim, Elif Sila
dc.contributor.authorKarabulut, Bulent
dc.contributor.authorUslu, Ruchan
dc.date.accessioned2019-10-27T10:01:30Z
dc.date.available2019-10-27T10:01:30Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: Inflammatory breast cancer (IBC) has an unfavourable prognosis despite the advances made in the treatment of breast cancer. Our study aimed to define immunohistochemistry-based surrogate subtype distribution to determine whether the breast cancer subtype accompanied survival outcome differences in IBC. Materials and Methods: Medical records of female breast cancer patients with non-metastatic inflammatory breast cancer admitted to our clinic between March 2000 and December 2015 were retrospectively reviewed. Patient demographics, clinical and pathological feature of the primary tumour, adjuvant treatment options and survival data were analysed. Intrinsic breast cancer subtypes were defined according to ER, PR, HER-2 and ki-67 status. Results: We identified 129 non-metastatic inflammatory breast cancer patients. Median follow-up was 73 months. 10 (7.7%) were luminal A-like, 67 (51.9%) were luminal B-like, 37 (28.6%) were HER-2 positive, and 15 (11.6%) were triple negative (TNBC) by immunohistochemistry. There were no statistically significant differences between subtypes in terms of histological type, grade, tumour size and lymph node status. Median disease-free survival was 47 months (95% confidence interval [CI] 29.2-82.6) and median overall survival was 75 months (95% CI 64.7-90.8). Triple negative breast cancer showed poorer outcome than other subgroups. Presence of TNBC disease was associated with poorer outcome compared to luminal A (HR: 0.19, 95% CI 0.04-0.92, p: 0.039), luminal B (HR: 0.34, 95% CI 0.15-0.74, p: 0.007) and HER-2 positive subgroups (HR: 0.40, 95% CI 0.17-0.94, p: 0.037). Luminal A patients had a trend to have a better overall survival which did not reach to a statistical significant difference. Conclusion: Our study put forth that IBC have a poor prognosis irrespective of breast cancer surrogate subtype distribution. Luminal A, the most frequent subtype of breast cancer was the least common in our IBC patient group. TNBC had the worst outcome when compared to other breast cancer subtypes.en_US
dc.identifier.doi10.5152/ejbh.2018.4170en_US
dc.identifier.endpage217en_US
dc.identifier.issn2587-0831
dc.identifier.issue4en_US
dc.identifier.pmid30288495en_US
dc.identifier.startpage211en_US
dc.identifier.urihttps://doi.org/10.5152/ejbh.2018.4170
dc.identifier.urihttps://hdl.handle.net/11454/29857
dc.identifier.volume14en_US
dc.identifier.wosWOS:000446223100005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofEuropean Journal of Breast Healthen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectInflammatory breast canceren_US
dc.subjectbreast cancer subtypesen_US
dc.subjectsurvivalen_US
dc.titleThe Impact of Subtype Distribution in Inflammatory Breast Cancer Outcomeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu